ArticleDiscover oncology2025
Driver gene-specific prevalence and incidence of brain metastases in non-small cell lung cancer: a meta-analysis encompassing all disease stages.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBrain metastases (BM) in non-small cell lung cancer (NSCLC) are associated with a poor prognosis. Identifying relevant genomic alterations can facilitate the targeting of therapies. We conducted a systematic review and meta-analysis to assess the prevalence and incidence of these alterations in NSCLC patients.
methodsPubMed, Embase and WOS were searched, from January 2000 to February 2024 using "lung", "met" and "incidence" as search phrases. We obtained data on the prevalence at diagnosis and the annual incidence of new BM in patients with EGFR, ALK, KRAS, and other genetic alterations. The pooled prevalence and incidence rates were calculated using a random effects model. This study is registered with PROSPERO (CRD42023491178).
resultsA total of 120 articles were included in the analysis. Prevalence data were derived from 94 studies (17,458 patients), while incidence data were obtained from 95 studies (13,323 patients). The pooled prevalence of BM at diagnosis was found to be 28.8% (95% [CI]: 0.263-0.313). This prevalence was highest among patients who were ALK-positive (31.6%) or had EGFR-positive (29.4%). The incidence rates were observed to be 0.086 in the EGFR group (95% CI 0.045-0.131), 0.062 in the ALK group (95% CI 0.003-0.122), 0.057 in the KRAS group (95% CI 0.000-0.188), 0.064 in the ROS1 group (95% CI 0.000-0.162), and 0.055 in the RET group (95% CI 0.000-0.224).
interpretationComprehensive meta-analyses indicate prevalence and incidence of BM are higher in patients with specific genomic alterations and advanced disease. Brain imaging and targeted therapies for brain penetrance are important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.